Rivaroxaban Market

Rivaroxaban Market Size, Share & Industry Analysis, By Source (Petroleum-Based, Bio-Based), By End-User (Pharmaceuticals & Healthcare, Food & Beverage, Cosmetics & Skincare, Chemical & Polymer Industry), and Forecast Period 2025-2035

The Rivaroxaban market is projected to grow at a CAGR of 6.1% from 2025 to 2035, driven by the increasing global incidence of venous thromboembolism (VTE), non-valvular atrial fibrillation (NVAF), and deep vein thrombosis (DVT), along with a growing preference for direct oral anticoagulants (DOACs) over traditional vitamin K antagonists. Rivaroxaban is a selective Factor Xa inhibitor that works by blocking the activity of Factor Xa, an essential component in the coagulation cascade, thereby preventing clot formation.

Market adoption is fueled by its once-daily dosing, oral administration, and predictable pharmacokinetics, which reduce the need for regular monitoring compared to warfarin. Rivaroxaban has gained wide regulatory approvals for various indications including stroke prevention in NVAF, treatment and secondary prevention of DVT/PE, and postoperative thromboprophylaxis after orthopedic surgeries. It is also increasingly used in combination therapies for coronary artery disease (CAD) and peripheral artery disease (PAD).

North America holds the largest market share due to high awareness of thrombotic disorders, favorable reimbursement policies, and strong physician preference for DOACs. Europe follows, with widespread adoption in both hospital and outpatient settings. The Asia-Pacific region is expected to experience the fastest growth, driven by increasing cardiovascular disease burden, aging population, and rising access to novel anticoagulants. Growth in Latin America and Africa is supported by expanding clinical use and entry of generics.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Rivaroxaban
Key End-Users & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Demand-Supply Dynamics

Segmental Outlook

By Source
Branded Rivaroxaban(e.g., Rituxan, MabThera)
Investigational Drug-GradeRitonavir
Key End-Use Industries
Ophthalmology Clinics
Hospitals
Retail Pharmacies
Online Pharmacies

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Trade Analysis

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, and Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Production Capacity
Company Profiles & Key Developments
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Polpharma
Inke S.A.
LGM Pharma
Metrochem API Private Limited
Rochem International Inc.
Suanfarma
Cohance Lifesciences
Reddy’s Laboratories
Egis Pharmaceuticals PLC
Jai Radhe Sales
Moehs Iberica
Faran Shimi Pharmaceutical
Aarti Pharmalabs
Ami Lifesciences Private Limited
HRV Global Life Sciences
Neuland Laboratories
Octavius Pharma Pvt. Ltd.
Tenatra Chemie
Cambrex Corporation

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 28, 2025

What is Rivaroxaban?

Rivaroxaban is an oral anticoagulant belonging to the class of direct Factor Xa inhibitors. It is used primarily to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation. By directly inhibiting Factor Xa, a key enzyme in the coagulation cascade, Rivaroxaban prevents the formation of thrombin and ultimately the development of blood clots. It offers advantages over traditional anticoagulants like warfarin, including fewer dietary restrictions, a fixed dosing regimen, and no requirement for routine blood monitoring. Rivaroxaban is marketed under the brand name Xarelto and is widely prescribed due to its proven efficacy and safety profile in various thromboembolic disorders.

What is the market growth of Rivaroxaban?

The global Rivaroxaban market is projected to grow at a CAGR of 5.6% from 2025 to 2035, increasing from approximately USD 9.8 billion in 2025 to about USD 16.9 billion by 2035. The market growth is driven by the increasing prevalence of cardiovascular disorders such as atrial fibrillation, venous thromboembolism, and the aging global population, which is more susceptible to thrombotic events. Additionally, the expanding use of Rivaroxaban in surgical settings for thromboprophylaxis and its inclusion in treatment guidelines for stroke prevention in atrial fibrillation further contribute to its rising demand. Patent expirations in some markets and the entry of generic versions may moderate pricing, helping to expand usage, particularly in emerging economies.

What are the drivers of the Rivaroxaban market?

Key drivers of the Rivaroxaban market include the growing incidence of atrial fibrillation and venous thromboembolism, conditions for which Rivaroxaban provides effective long-term management. The drug’s oral administration, fixed dosing, and lack of need for regular INR monitoring make it a preferred option over older anticoagulants like warfarin. Furthermore, its expanded indications for use in treating and preventing recurrence of DVT and PE, as well as in patients undergoing hip or knee replacement surgeries, have broadened its clinical utility. Rising awareness among patients and healthcare providers, increasing diagnosis rates, and supportive reimbursement policies are additional factors contributing to market growth.

Who are the key players operating in the Rivaroxaban market?

The primary player in the Rivaroxaban market is Bayer AG, which developed the drug in collaboration with Johnson & Johnson. Bayer markets Rivaroxaban under the brand name Xarelto in most countries, while Johnson & Johnson’s Janssen Pharmaceuticals holds marketing rights in the U.S. As the drug faces patent expiry in some markets, several pharmaceutical companies are preparing or have launched generic versions, including companies like Teva Pharmaceuticals, Mylan, and Aurobindo Pharma. These players are expected to further stimulate competition and improve affordability and access to Rivaroxaban globally.

Which region will exhibit the fastest growth in the Rivaroxaban market?

The Asia-Pacific region is expected to witness the fastest growth in the Rivaroxaban market, driven by rising cardiovascular disease burden, increasing healthcare spending, and growing awareness about stroke prevention and anticoagulation therapy. Countries like China and India are experiencing a sharp rise in the prevalence of atrial fibrillation and thromboembolic disorders due to aging populations and lifestyle changes. Additionally, as generic versions of Rivaroxaban become available, affordability and access in these markets are expected to improve significantly. While North America and Europe will continue to lead in terms of market share due to high diagnosis rates and established healthcare systems, growth in these regions may be more moderate compared to the rapid expansion seen in emerging economies.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com